Targeting BRAF for patients with melanoma

作者：H-T. Arkenau, Richard F. Kefford, Georgina Venetia Long · 发表于：British Journal of Cancer · 年份：2010 · DOI：10.1038/sj.bjc.6606030 · 被引用次数：138 · 研究领域：Melanoma and MAPK Pathways、Computational Drug Discovery Methods、HER2/EGFR in Cancer Research

The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising activity in early clinical development and particular interest is focused on selective inhibitors of mutant BRAF, which is present in one half of the cases of metastatic melanoma. The majority of patients on early trials of these drugs develop secondary resistance and subsequent disease progression and it is, therefore, critical to understand the underlying escape mechanisms leading to resistance.